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Aims: Hyperglycemia leads to increased production of reactive oxygen species (ROS), which
reduces cellular antioxidant defenses and induces several DNA lesions. We investigated the
effects on DNA damage of a seven-day hospitalization period in patients with type 2
diabetes mellitus (T2DM) to achieve adequate blood glucose levels through dietary inter-
vention and medication treatment, compared with non-diabetic individuals.
Methods: DNA damage levels were evaluated by the alkaline comet assay (with modified
and without conventional use of hOGG1 enzyme, which detects oxidized DNA bases) for 10
patients and 16 controls. Real time PCR array method was performed to analyze the
transcriptional expression of a set of 84 genes implicated in antioxidant defense and
response to oxidative stress in blood samples from T2DM patients (n = 6) collected before
and after the hospitalization period.
Results: The seven-day period was sufficient to improve glycemic control and to signifi-
cantly decrease ( p < 0.05) DNA damage levels in T2DM patients, although those levels were
slightly higher than those in control subjects. We also found a tendency towards a decrease
in the levels of oxidative DNA damage in T2DM patients after the hospitalization period.
However, for all genes analyzed, a statistically significant difference in the transcriptional
expression levels was not observed.
Contents available at ScienceDirect
Diabetes Research
and Clinical Practice
journal homepage: www.elsevier .com/locate/diabres* Corresponding author at: Department of Biology—Faculty of Philosophy, Sciences and Letters of Ribeira˜o Preto, University of Sa˜o
Paulo—USP, Av. Bandeirantes, 3900, 14040-901, Ribeira˜o Preto, SP, Brazil. Tel.: +55 16 3602 3827; fax: +55 16 3602 0222.
E-mail addresses: etshojo@usp.br, etshojo@gmail.com (E.T. Sakamoto-Hojo).
http://dx.doi.org/10.1016/j.diabres.2014.06.004
0168-8227/# 2014 Elsevier Ireland Ltd. All rights reserved.
Conclusions: The study demonstrated that although the transcriptional expression of the
genes studied did not show significant alterations, one-week of glycemic control in hospital
resulted in a significant reduction in DNA damage levels detected in T2DM patients,
highlighting the importance of an adequate glycemic control.
# 2014 Elsevier Ireland Ltd. All rights reserved.
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T2DM is a chronic, progressive, heterogeneous, and poorly
understood metabolic disease, which develops as a conse-
quence of insulin resistance and pancreatic b-cell dysfunc-
tion, leading to extracellular hyperglycemia [1–3]. It is
estimated that 382 million people have diabetes worldwide,
with T2DM accounting for approximately 90% of all diagnosed
cases [4]. In addition, the prevalence of T2DM has increased
dramatically, mainly due to a high-calorie diet and sedentary
lifestyle, which contribute to excess body weight [5]. Hyper-
glycemia is widely recognized as a link between diabetes and
diabetic complications [3,6]. One of the major hypotheses to
explain the onset of diabetic complications is the increase in
oxidative stress due to the accumulation of reactive oxygen
species (ROS) as a consequence of hyperglycemia [3,7].
ROS accumulation can lead to the depletion of cellular
antioxidant defenses, such as vitamins E and C as well as
glutathione peroxidase [10]. Consistent with the fact that
hyperglycemia can trigger ROS generation, reduced levels of
glutathione have been reported both in cells exposed to high
glucose concentrations and in leukocytes of patients with
diabetes [8,9], suggesting that the antioxidant defense system
is compromised in those patients [10]. Also, in T2DM, signaling
pathways may be deregulated, such as fatty acid metabolism,
protection against lipid-induced oxidative stress, pro-inflam-
matory cytokines, and DNA repair [11].
In addition, overproduction of ROS can induce several DNA
lesions, including oxidized bases, abasic sites, DNA strand
breaks, and DNA-protein cross-links [12]. The 8-position ofTable 1 – Clinical characteristics of patients with type 2 diabe
Patient Age
(years)
Gender Height
(cm)
BH 
Fasting
Plasma
glucose
(mmol/L)
HbA1c
(% mmol/
mol)
Wei
(kg)
1 30 M 174 8.9 8.6–71 101
2 38 M 171 8.1 8.0–64 96
3 44 F 153 12.3 6.9–52 57
4 45 F 154 12.2 9.8–84 74
5 37 F 160 19.4 13.2–121 97
6 61 M 168 13.3 10.6–92 84
7 33 F 159 4.9 11.8–106 77
8 64 F 145 10.2 12.0–108 39
9 51 F 166 9 9.7–83 100
10 61 F 157 14.3 8.5–69 75
BH: before hospitalization; AH: after hospitalization; HbA1c: glycated hem
MN: mild nephropathy; NA: not avaliable. X: denotes the presence of thguanine is highly susceptible to ROS attack, generating 8-
hydroxy-20-deoxyguanosine (8-OHdG) [13]. The latter is an
extensively studied DNA lesion and has been considered as a
biomarker of oxidative DNA damage [14]. Furthermore, several
studies have reported high levels of 8-OHdG in peripheral
blood lymphocytes from patients with diabetes [15,16]. The
presence of 8-OHdG can be measured by the alkaline comet
assay employing the hOGG1 enzyme, a glycosylase that
removes 8-OHdG, generating alkali-labile sites, which causes
DNA breaks that can be detected by the comet assay [14].
Extracellular chronic hyperglycemia leads to increased
oxidative stress due to an elevated generation of ROS [3,7,17],
which, in turn, can cause DNA lesions [12]. The present study
aimed to investigate the effects of a seven day-glycemic
management on the levels of DNA damage in T2DM patients
compared with the control group (individuals without diabetes)
by performing the alkaline comet assay. In addition, we aimed
to examine whether the intervention affects the transcriptional
expression levels of a gene set with roles in oxidative stress
and antioxidant defense, by comparing samples obtained
from patients with T2DM before and after hospitalization.
2. Subjects
A total of 10 T2DM subjects (3 males and 7 females)
participated in the present study, aged between 30 and 61
years (mean 46.4  12.3 years) and with an average duration
of diabetes of 6.9 years. The main clinical characteristics
are described in Table 1. All patients were hospitalized for ates mellitus.
AH HT DLP MR MN
ght Fasting
plasma
glucose
(mmol/L)
HbA1c
(% mmol/
mol)
Weight
(kg)
 5.7 8.4–68 96 X X – –
 4.8 7.6–60 93.5 – – X –
 10.8 6.9–52 56.5 – – – –
.7 4.3 8.3–67 73.1 – X – –
.5 11.6 12.8–116 94.3 X – – –
 6.8 9.3–78 82.2 X X – X
.4 4.4 10.3–89 NA – – – –
 4.6 12.8–116 39.6 – X X –
 5.2 7.5–59 95 X X – –
 5.2 8.0–64 73.1 – X – –
oglobin; HT: hypertension; DLP: dyslipidemia; MR: mild retinopathy;
e corresponding comorbidity.
Table 2 – Medication utilized for the treatment of each
type 2 diabetes mellitus patients. HCTZ: hydrochlor-
othiazide; ASA: acetylsalicylic acid; U: units. #: medica-
tion withdrawn from the treatment after the beginning of
hospital intervention; *: medication introduced to the
treatment after the beginning of hospital intervention.
Drug dosage per day is shown in parenthesis and when
modified during intervetion, previous and posterior
doses are separated by a hyphen (previous - posterior).
PatientMedication
1 Insulin (50/50–46/42 U), metformin (1000 mg)*,
HCTZ (25 mg)*, fenofibrate (250 mg), captopril (400 mg)
2 Metformin (850 mg), glibenclamide (5 mg)
3 Insulin (8/20 U), metformin (1000 mg)*, bromopride (30 mg)
4 Insulin (44/32 U), metformin (2550 mg), sinvastatin (40 mg),
ASA (100 mg)
5 Insulin (10/30 U), metformin (1500 mg), HCTZ (50 mg),
ASA (100 mg), captopril (40 mg)*
6 Insulin (42/30 U), metformin (1700 mg), fenofibrate
(250 mg),
HCTZ (50 mg), captopril (75 mg)
7 Insulin (36/24 U), metformin (1700 mg), glibenclamide#
8 Insulin (10/8 U)*, metformin (1000 mg), atorvastatin
(10 mg)*,
ASA (100 mg), prednisone (5 mg)
9 Insulin (70/45 U), metformin (1500 –1700 mg),
glibenclamide (5 mg)*, HCTZ (50 mg), captopril (75–150 mg)
10 Insulin (34/26 U), metformin (1500 mg), atorvastatin
(10 mg), ASA (100 mg)
Table 3 – Levels of fasting plasma glucose and glycated
hemoglobin in controls and in T2DM patients pre- and
post-hospitalization. The values represent the mean -
W standard deviation calculated for 10 T2DM patients
and 12 healthy subjects. BH: before hospitalization; AH:
after hospitalization; HbA1c: glycated hemoglobin. #
Denotes p < 0.05 compared with the corresponding BH
value; * Denotes p < 0.05 compared with the correspond-
ing control value.
Subjects Fasting plasma
glucose (mmol/L)
HbA1c
(% mmol/mol)
Control (n = 12) 5.2  0.4 5.5  0.2  36  2.4
T2DM/BH (n = 10) 11.3  3.9* 9.9  2.0*  84.8  21.8*
T2DM/AH (n = 10) 6.3  2.7# 9.2  2.1*  76.9  23.3*
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glycemic control, with levels close to normal (3.9–
6.1 mmol/L). During this period, patients received a
dietary intervention which was in general similar for all
patients. All received a diabetic diet with low sugar
content and the meals were more fractionated. Patients
with hypertension also received a low sodium diet and
those with dyslipidemia also received a low fat diet.
Some patients had a night light meal, while others did
not. Males T2DM received a 2000 kcal/day diet and females
a diet varying between 1500 and 1800 kcal/day. All
patients were on blood glucose lowering medications
which were modified as necessary (Table 2). All patients
received metformin, while nine patients were treated
with insulin (Table 2). Fasting plasma glucose (mmol/L)
and HbA1c (%–mmol/mol) levels were measured before
hospitalization (BH) and after hospitalization (AH) (Tables 1
and 3). BH mean fasting glucose and HbA1c were 11.3 mmol/
L and 9.9%, respectively. Patients with late diabetic
complications (such as proliferative retinopathy, consoli-
dated nephropathy, kidney failure, heart disease, and
autonomic neuropathy) were excluded, since these condi-
tions might lead to elevated oxidative stress. The control
group consisted of 16 healthy subjects (7 males and 9
females) between the ages of 36 and 65 years (mean
52.9  6.7). Exclusion criteria for the control group included
family history of diabetes or chronic diseases, exposure to
radiation, infections, and use of medications. Levels of
fasting plasma glucose and HbA1c were measured in 12
of the 16 healthy individuals (Table 3). The study protocol
was approved by the Ethics Committee of the ClinicalHospital and informed written consent was obtained from
all subjects.
3. Material and methods
3.1. Sample collection, isolation of peripheral blood
mononuclear cells, and RNA extraction
Peripheral blood samples (20 mL) from T2DM patients (n = 10)
were collected via standard venipuncture into tubes contain-
ing EDTA (Beckton & Dickinson, USA), before and seven days
after admission of patients to the hospital.
For the detection of DNA damage, fresh peripheral blood
samples (25 mL) from patients with diabetes and healthy
individuals (n = 16) (also collected via standard venipuncture)
were used for the single-cell gel electrophoresis (comet assay)
method.
Regarding only the patients, the remaining amount of
peripheral blood mononuclear cells (PBMCs) were isolated
by density gradient centrifugation using Histopaque-1077
(Sigma–Aldrich Inc., USA). Total RNA was extracted from
the PBMCs using the Trizol reagent (Invitrogen, Rockville, MD,
USA), according to the manufacturer’s instructions. RNA was
quantified by Genequant Spectrophotometer (Amersham,
USA), and its quality and integrity were assessed both by
agarose gel electrophoresis, as well as by microcapillary
electrophoresis on Agilent RNA Nano 6000 chips and Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
RNA samples were used for PCR array only if protein- and
phenol-free and with RNA integrity number (RIN) values  8.0.
3.2. Single cell gel electrophoresis (comet assay) - Alkaline
condition
The alkaline comet assay was conducted according to Singh
et al. [18], with slight modifications. All steps were performed
under dim light to minimize further DNA damage occurrence.
Two hundred microliter of 0.5% low melting agarose (37 8C)
were added to each sample of peripheral blood (25 mL) from
T2DM patients (collected before and after hospitalization)
and from control subjects, followed by gently resuspension.
The cellular suspensions were distributed onto microscope
slides that had been pre-coated with a layer of 1.5% normal
melting agarose. The gel layers on the slides were covered
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for 5 min at 4 8C. After removing the coverslips, the slides were
immersed in a cold lysis solution (2.5 M NaCl, 100 mM Na2EDTA,
10 mM Tris, 1% Triton X-100, and 10% DMSO, pH = 10.0) for at
least 12 h at 4 8C. Next, the slides containing the nuclei were
incubated in electrophoresis solution (0.3 M NaOH and 1 mM
Na2EDTA, pH > 13) for 20 min at 4 8C to allow the DNA to
denature, followed by electrophoresis at 25 V (1 V/cm, 300 mA)
for 20 min at 4 8C. Subsequently, the slides were incubated
in neutralization buffer (0.4 M Tris–HCl, pH = 7.5) for 15 min,
air-dried at room temperature, and fixed in absolute ethanol
for 5 min at room temperature.
Nuclei were stained with 50 mL of propidium iodide (25 mg/
mL) and examined under a Carl Zeiss epifluorescence
microscope equipped with an excitation filter of 516–560 nm
and a barrier filter of 590 nm, using a 40 objective. The images
were captured using Axiocan camera (Zeiss) and the AxioVi-
sion 3.1 program (Zeiss) with live imaging facility.
Hydrogen peroxide was used as a positive control for the
comet assay itself (data not shown). Each time electrophoresis
was conducted, after the lysis step, 80 mM of hydrogen
peroxide were added to the gels containing blood samples
from two randomly selected individuals for 15 min. The other
steps of the assay were carried out as aforementioned.
3.3. Modified comet assay
The modified comet assay was conducted according to
Smith et al. [19]. To detect 8-OHdG, a modified comet assay
using the hOGG1 enzyme was performed for the same groups
aforementioned. All the steps previously described for the
conventional comet assay were performed with a few
modifications. After lysis, the slides were washed with 1
phosphate buffered saline (PBS) free of Ca2+ and Mg2+ for
5 min at 4 8C, and then immersed in two changes of buffer
F (40 mM HEPES, 0.1 M KCl, 0.5 mM EDTA, and 0.2 mg/mL
bovine serum albumin, pH = 8.0) for 5 min at room tempera-
ture. Afterwards, 0.08 U hOGG1 (New England Biolabs) in
50 mL of buffer F was added to the gel layers, which were
covered with coverslips and placed in a humidified
chamber (Hybrite, Vysis) for 20 min at 37 8C. Slides treated
only with buffer F were also prepared to verify if the buffer
alone could induce DNA damage. After the enzyme treat-
ment, the other steps (electrophoresis, neutralization, and
fixation) were performed as in the conventional method.
3.4. Gene expression profiling - Quantitative real time
RT-PCR array
The expression of 84 genes (with roles related to oxidative
stress and antioxidant defense) was analyzed for 6 T2DM
patients (pre- and post-hospitalization) using the RT2 Profi-
lerTM PCR Array (SA Biosciences, Qiagen, USA). The plates
include 89 primers, with five of them corresponding to
housekeeping genes, as well as quality control elements for
the detection of genomic DNA contamination and assessment
of reverse transcription and PCR reactions. The experiments
were performed following the manufacturer’s instructions.
Briefly, 1 mg of total RNA was reverse transcribed using the RT2
First Strand Kit (SA Biosciences, Qiagen, USA), and theresulting cDNA was mixed with RT2 SYBR Green ROX qPCR
Mastermix (SA Biosciences, Qiagen, USA). Next, 25 mL of
the mixture was added to each well of the RT2 Profiler PCR
arrays, which was sealed with Optical Thin-Wall 8-Cap Strips.
The PCR reaction was run on an Applied Biosystems
model 7000 real-time cycler according to the following
cycling program: a pre-warming step of 10 min at 95 8C to
activate the DNA Taq Polymerase, followed by 40 cycles of 15 s
at 95 8C and 1 min at 60 8C.
3.5. Data analysis and statistics
3.5.1. Glycemic levels
To compare the levels of fasting glucose and HbA1c among the
three groups (controls, BH, and AH), Kruskal–Wallis one way
analysis of variance on ranks, followed by all pairwise multiple
comparison procedures (Dunn’s method) were performed
using the SigmaStat program, version 3.5. Results were
presented as means  standard deviation and significance
levels were considered for p < 0.05.
3.5.2. Alkaline comet assay
DNA damage was analyzed for the two T2DM groups, BH and
AH, as well as for the control group. A total of 50 nuclei per
slide were randomly scored using the CometScore program,
version 1.5 (Tritrek Corp., USA). Only nuclei that did not
overlap and presented clear margin delimitation were exam-
ined. As a measurement of DNA damage, the tail intensity (TI),
which is the percentage of DNA migrated from the head of the
comet into the tail, was recorded for each nucleus scored. For
the slides treated with hOGG1 enzyme, analyzed TI values
correspond to DNA strand breaks plus hOGG1 sensitive sites.
To compare the levels of DNA damage and the effects of
hOGG1 among the three groups (control, BH, and AH), Two
Way Analysis of Variance, followed by Student–Newman–
Keuls test were applied to the data. In addition, to analyze the
effects of the seven day-hospitalization period on the DNA
damage levels presented by T2DM patients, paired t-test was
applied to the results, which were presented as mean-
s  standard deviation, and significance levels were consid-
ered for p < 0.05.
3.5.3. Gene expression profiling - Quantitative real time
RT-PCR array
After determining the threshold cycle (Ct) for each well of the
array, the data were analyzed using the web-based RT2 Profiler
PCR Array Data Analysis software, version 3.5 (http://pcrda-
taanalysis.sabiosciences.com/pcr/array analysis.php). The
threshold cycle for each well was uploaded into the software,
which, in turn, performed the fold-change calculations based
on DDCt (AH versus BH), with the statistical significance
threshold being set to 0.05.
4. Results
4.1. Glycemic levels
For the 10 T2DM patients, the one-week intervention decrease
glucose levels, particularly patients 4, 5, 6, 8, and 10. As
Fig. 1 – DNA damage levels analyzed by the comet assay in blood cells of T2DM patients pre- and post-hospitalization
compared with the control group. DNA damage levels are expressed as tail intensity. Mean values were calculated for 10
T2DM patients and 16 healthy individuals. Bars represent standard deviation. BH: before hospitalization; AH: after
hospitalization; (S) hOGG1: conventional comet assay; (+) hOGG1: modified comet assay. # Denotes p < 0.05 compared with
the corresponding BH value. * Denotes p < 0.05 compared with the corresponding control value.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 5 ( 2 0 1 4 ) 3 5 6 – 3 6 3360expected, seven days of treatment only slightly reduced HbA1c
values (Table 1). Glucose levels were significantly ( p < 0.05)
lower in the control group compared with the BH group;
interestingly, there was a statistical difference ( p < 0.05) in
glucose levels between the AH and the BH group, while a
statistical difference was not observed between the AH and
the control group (Table 3). HbA1c levels were significantly
( p < 0.05) higher in the T2DM groups BH and AH relative to the
healthy control group, while there was no significant differ-
ence between the AH and BH (Table 3).
4.2. DNA damage levels
By performing the conventional comet assay, both T2DM
groups (BH and AH) presented significantly ( p < 0.05) higher TI
mean values (6.69  3.68 and 4.38  3.00, respectively) than
that of the control group (2.57  1.37). Interestingly, the AH
group presented significantly ( p < 0.05) lower TI mean values
than the BH group (Fig. 1), indicating that a one-week
intervention period was efficient to reduce DNA damage
levels.
Regarding the results obtained from the modified comet
assay, the TI mean values were significantly ( p < 0.05) greater
in both BH (8.51  3.17) and AH (6.06  1.69) groups relative
to the group of healthy subjects (4.33  1.91). Moreover,
although the difference in the TI mean values was not
significant ( p > 0.05), a tendency towards a decrease in the
levels of oxidative DNA damage was observed in the AH
compared with the BH group ( p < 0.06) (Fig. 1).Table 4 – Genes with high fold-change values in the AH group
Accession number Gene symbol Gene n
NM_001159 AOX1 Aldehyd
NM_007158 CSDE1 Cold sh
NM_203472 SELS Selenop
AH: after hospitalization; BH: before hospitalization.4.3. Gene expression profiling
For six T2DM patients submitted to the one-week interven-
tion, expression profiles of 84 genes with roles related to
oxidative stress and antioxidant defense pathways were
simultaneously analyzed. The results indicated a lack of
significant changes in gene expression levels between the
two groups. However, three genes, namely AOX1, CSDE1, and
SELS, were highlighted since they presented considerably
high fold change (FC) values: 3.29, 6.01, and 3.06, respec-
tively (Table 4, Fig. 2).
5. Discussion
We investigated whether a seven-day hospitalization period
aiming to improve glycemic control affected levels of DNA
damage in peripheral blood cells from T2DM patients
compared with subjects without diabetes. In addition, we
examined the expression profiles of genes involved in
oxidative stress and antioxidant defense in peripheral blood
cells from the before and after hospitalization in T2DM to
detect changes at the transcriptional level between the two
groups. One week of treatment was sufficient to lower
glucose values close to the normal range. On the other hand,
as expected, HbA1c levels were only slightly decreased
after hospitalization.
Levels of DNA damage in peripheral blood cells measured
by the alkaline comet assay allows the detection of DNA compared with the BH group.
ame Fold change
e oxidase 1 3.29
ock domain containing E1, RNA-binding 6.01
rotein S 3.06
Fig. 2 – Volcano plot representing the expression profiles of genes involved in oxidative stress and antioxidant defense
pathways from six T2DM patients. Volcano plot analysis revealed the absence of genes with significant expression in AH
relative to BH patients. Each open circle represents one out of the 84 genes analyzed by PCR array. The three genes with
high FC values are represented in color; red color indicates up-regulation; green color indicates down-regulation. The
X-axis displays the FC values in log 2 for T2DM patients, AH versus BH group. The Y-axis displays the p-values in Slog 10.
AH: after hospitalization; BH: before hospitalization; FC: fold-change. (For interpretation of the references to color in this
figure legend, the reader should access the online version of the article.)
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low levels of damage [20]. Our study showed a significant
decline in DNA damage levels in T2DM patients after the
intervention period which is consistent with reports of
increased levels of DNA damage in lymphocytes from
poorly-controlled patients with diabetes [21]. On the other
hand, similarly to the results showed by Tatsch et al. [21],
our findings showed that DNA damage levels were still
elevated in both T2DM groups relative to the controls.
Although normal rates of DNA damage were not achieved
in our T2DM patients, the seven-day treatment resulted in
a significant reduction in damage levels and elevatedDNA damage levels have been associated with the develop-
ment of incident diabetic complications [22].
Hyperglycemia in T2DM patients causes glucose auto-
oxidation, non-enzymatic protein glycation, and other meta-
bolic alterations that lead to increased ROS production [9,23].
Since all macromolecules can be affected by ROS, including
DNA [24], a modified comet assay using the hOGG1 enzyme
was performed on peripheral blood cells from T2DM
patients (BH and AH) and subjects without diabetes, aiming
to detect 8-OHdG, one of the most recurrent and extensively
studied oxidative DNA lesions [25]. The hOGG1 enzyme is a
glycosylase involved in the first steps of the base excision
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8-OHdG generated as a consequence of hyperglycemia
[27,28]. Our findings of a tendency towards a reduction in
the levels of oxidative damage ( p < 0.06) was observed
after the hospitalization period indicating that after the
seven-day intervention period to improve glycemic control,
there was a slight recovery of oxidative DNA damage,
reinforcing the association between hyperglycemia, in-
creased levels of ROS, and DNA damage.
Similar to our study, Dincer et al. [10] analyzed oxidative
DNA damage in leukocytes from T2DM patients (by the comet
assay) and described significantly elevated levels of oxidative
damage in controlled patients (categorized according to their
levels of HbA1c) relative to healthy subjects. In addition,
consistent with our findings regarding a tendency towards
decreased levels of oxidative damage, the same authors
observed significantly lower levels of oxidative damage in
patients with good glycemic control when compared to those
with poor control [10]. Moreover, even though Lodovici et al. [9]
have shown that T2DM patients exhibited significantly
higher levels of oxidative DNA damage in leukocytes com-
pared with healthy individuals, they found a positive
association between antioxidant capacity and glucose or
HbA1c levels in poorly controlled T2DM subjects, which is
in accordance with the assumption that antioxidant capacity
is improved to compensate the excess of free radical species.
A limitation of our study is the sample size (n = 10) and a
larger number of individuals analyzed may have resulted in
the detection of a significant difference in oxidative damage.
In addition the treatment period of 7 days may have been too
short. Finally, sample heterogeneity and genetic background
should be considered as well, since it may also influence the
results.
We also examined mRNA levels of genes related to
oxidative stress and antioxidant defense. We found that none
of the 84 genes investigated showed significant differences in
expression profiles in the AH group compared with the BH
group. This too may been related to the small sample size and
short duration of the intervention. Interestingly three genes
displayed considerably high fold change values: AOX1, CSDE1,
and SELS (Table 4, Fig. 2). AOX1 gene belongs to a family of
enzymes whose role is to catalyze the oxidation of aldehyde
compounds and nitrogenous heterocyclic xenobiotics, with
high levels of this enzyme being present in the human liver
[29,30]. Although involved in the metabolism of a mutagenic
adduct (M1dG) [31], AOX1 has also been implicated in the
production of two reactive oxygen species: superoxide and
hydrogen peroxide [32]. The rat protein Tanis, whose human
homologue protein is SELS [33], has been implicated in a tight
relationship with glucose. We observed higher levels of SELS
in T2DM patients before the seven-day hospitalization period
compared with those after the intervention period. The
protein encoded by the gene CSDE1, also known as UNR, binds
to purine-rich sequences [34]. CSDE1 is one of the five
proteins associated with the c-fos major protein-coding-
region determinant of instability (mCRD), which mediates
mRNA decay coupled to translation [35]. Besides that, it has
been reported that CSDE1 also participates in the regulation of
cell death. The same authors reported that human hepatoma
cell line HuH7, knocked down for CSDE1, presented increasedapoptosis and necrosis both before and after radiation
exposure. Our findings indicated a down-regulation of CSDE1
in the BH group that presented high glucose levels, which in
turn, could be linked to the formation of ROS through many
pathways [9,23], leading to DNA damage induction [24]. These
results may suggest that mRNA decay, as well as cell death
pathways may be deregulated in T2DM patients exhibiting
poor glycemic control.
In conclusion, the present study demonstrated that a
seven-day intervention to achieve adequate blood glucose
levels lead to a significant decrease in DNA damage in T2DM
patients, even though those levels were slightly higher than
those in individuals without diabetes. We also observed a
tendency towards a reduction in the levels of oxidative DNA
damage after the hospitalization period, although none of
the genes related to antioxidant defense and response to
oxidative stress were differentially expressed.
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